Source: Jpn J Clin Hematol  |  Posted 5 years ago

PARIS, FRANCE -- February 20, 2006 -- Sanofi-aventis announced today that it has received from the U.S. Food and Drug Administration (FDA), Division of Metabolism and Endocrinology Products an approvable letter for rimonabant for weight management, and from the Division of Anesthesia, Analgesia and Rheumatology Products a non approvable letter for smoking cessation.

Sanofi-aventis will continue to work in close collaboration with the FDA.

Rimonabant is the first in a new class of therapeutic agents called CB(1) blockers.

SOURCE: sanofi-aventis